Navigation Links
IDRI and Medicago report positive results for Phase I clinical trial for an H5N1 vaccine
Date:4/17/2013

order to collect and compare data.

The trial focused on evaluating the safety and immunogenicity of the H5N1 vaccine, combined with IDRI's GLA adjuvant, which has been exclusively licensed to Immune Design Corp for certain fields, including influenza. The vaccine was administered intramuscularly or intradermally. The intradermal route of administration was also tested in comparison with intramuscular delivery, using an FDA licensed device (MicronJet600, NanoPass Technologies) as the micro-needle device was previously shown in seasonal and pandemic flu tests to allow significant dose sparing. This study is among the first to test intradermal adjuvants and is the first time GLA has been tested intradermally.

Safety and Immunogenicity Results

The H5N1 vaccine candidate has been tested in over 300 healthy volunteers to date, none of which have experienced any serious adverse reactions. The H5N1 vaccine candidate was found to be safe and well tolerated. As planned in the clinical design, monitoring of adverse events will continue for one year.

All three configurations of adjuvant and route of administration for 20ug of the H5N1 vaccine candidate induced a solid immune response against the H5N1 viral strain that exceeded the CHMP immunogenicity criteria for licensure of influenza vaccines which are 40% seroconversion, 70% seroprotection and 2.5x geometric mean increase (GMI). For a 20ug dose of the H5N1 vaccine plus; 2.5ug GLA-AF administered intradermally (ID), 2.5ug GLA-AF delivered Intramuscularly (IM) and 0.5ug alum formulation administered IM, a four-fold increase in HI titers (seroconversion) was observed in 65.0%, 80.0% and 83.3% of subjects, respectively. The seroprotection rate was 70.0%, 85.0% and 89.9%, respectively. The GMI was 10.3x, 8.7x, and 11.4x, respectively.

About H5N1

According to the Centers for Disease Control and Prevention, the highly pathogenic avian influenza A (H5N1) virus is a
'/>"/>

Contact: Lee Schoentrup
lee.schoentrup@idri.org
206-858-6064
Infectious Disease Research Institute
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. IDRI and Medicago to present data at the World Vaccine Congress
2. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
3. U.S. Infant Mortality Rates Finally Dropping Again: Report
4. Molecule treats leukemia by preventing cancer cell repair, Jackson Laboratory scientists report
5. Rally in Support of Child Victims Act Kicked off Yesterday in New York, Reports Alonso Krangle
6. New study finds digoxin safe despite recent reports
7. Magnet hospitals achieve lower mortality, reports Medical Care
8. St Jude Retreats Releases New Infographic Which Reports Consequences of Drunk Driving
9. First NuvaRing Lawsuits in State, Federal NuvaRing Litigations Set to Head to Trial Later This Year, Alonso Krangle LLP Reports
10. Lucintel Report Outlines $100 Billion Market for Global Oncology Drugs Industry in 2018
11. Rescheduling of First NuvaRing Lawsuit Trials in State, Federal NuvaRing Lawsuit Litigation, Reports Wright & Schulte LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Two sisters ... and heart damage. Ilina and Medha Krishen use ... for sounds of trouble in breathing patterns or heartbeats. ... School in Michigan, wanted to find a way to ... air pollutants. Using an electronic stethoscope, Ilina recorded one ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Measures taken by Firestone ... Ebola-ravaged Liberia may have limited the spread of the ... The Firestone Natural Rubber Co. provides health services ... of nearby densely populated communities. Between Aug. 1 ... Ebola cases among those 80,000 people. That incidence rate ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... a booth at the American Foundation for Suicide Prevention’s ... The AFSP is a not-for-profit organization that hosts hundreds ... proceeds from these events are used to help understand ... education and personal relationships as well. , The ...
(Date:10/20/2014)... October 20, 2014 T.E.N., a ... firm, announced today that William H. Murray, renowned ... 2014 ISE® Luminary Leadership Award winner. Presented annually, ... of an outstanding leader and industry practitioner for ... in advancing the information security industry. , Formerly ...
Breaking Medicine News(10 mins):Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... The Michigan,Chamber of Commerce today announced its opposition to ... to the November 2008 ballot and,constitutionally require the Legislature ... Michigan Chamber cited serious concerns with the,wide open and ... Michigan job providers and taxpayers would need to write ...
... greats competing in the,annual Liberty Mutual Legends of Golf ... and participate in demonstrations of robotic surgery on,Saturday, April ... Last fall, St. Joseph,s/Candler Health System in Savannah ... surgery using Intuitive,Surgical,s da Vinci S Surgical System., ...
... Milan Joins Nonprofit Health Systems Research Institute as New Vice ... ... Jr., prominent leader,and advocate on HIV/AIDS issues, has joined the nonprofit Altarum ... "When we began the search for someone to lead our Community Health,Systems ...
... Exceptional Patient Care, HOUSTON, April 25 ... a veteran nurse in The Breast Center,has been ... Tenet Healthcare,Corp.,s (NYSE: THC ) highest award ... http://www.newscom.com/cgi-bin/prnh/20080425/LAF045 ), For 35 years, Valdez has ...
... find connection between measles, HPV and most common lung ... smoking is well-established as an independent risk factor for ... viral infections might boost a smoker,s already substantial risk ... at issue -- human papillomavirus (HPV) and measles -- ...
... The National Education Alliance for,Borderline Personality Disorder ... commended the U.S. House of Representatives for its,recent ... On April 1, 2008, the House of ... 1005) sponsored by Representatives,Thomas Davis (R-VA) and Chris ...
Cached Medicine News:Health News:Michigan Chamber of Commerce Opposes 'Blank Check' Healthcare Ballot Proposal 2Health News:Legends Golf Pros Receive Robotic Surgery Demos 2Health News:Prominent Advocate on HIV/AIDS Issues Joins Altarum Institute 2Health News:Houston Northwest Medical Center Caregiver Honored by Tenet Healthcare 2Health News:Possible Viral Links to Lung Cancer Risk Uncovered 2Health News:Possible Viral Links to Lung Cancer Risk Uncovered 3Health News:U.S. House of Representatives Supports May as Borderline Personality Disorder Awareness Month An Important Step in Raising Awareness 2
(Date:10/22/2014)... Oregon , October 22, 2014 ... "Global Disposable Gloves Market (Product type, Form, End user, ... Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... global disposable gloves market. Based on key trends tracked, ... be valued at $7.9 billion by 2020, registering a ...
(Date:10/22/2014)... , October 22, 2014 ... ), a clinical-stage pharmaceutical company focused on the ... positive top-line clinical results from its Phase IIa ... insulin capsules, to treat type 1 diabetes. The trial ... under a U.S. Food and Drug ...
(Date:10/22/2014)... 2014 Abaxis, Inc. (NasdaqGS: ABAX ... systems, today reported financial results for the second fiscal ... overview: , Revenues of $53.9 million, up 18% ... of $0.24, up 33% over last year,s comparable quarter. ... Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, up ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... Pa., Nov. 5, 2010 SAFE IN COMMON, an ... and individuals, today announced the launch of its website ... SAFE IN COMMON,s launch coincides with the ... and Prevention Act, which mandates the use of safety ...
... ATLANTA, Nov. 5, 2010 Cimzia® (certolizumab ... moderate to severe rheumatoid arthritis (RA) symptoms, reducing disease ... during the American College of Rheumatology,s 2010 Annual Scientific ... indicated for the treatment of adult patients with moderately ...
Cached Medicine Technology:SAFE IN COMMON Launches Global Injection Safety Website 2SAFE IN COMMON Launches Global Injection Safety Website 3SAFE IN COMMON Launches Global Injection Safety Website 4Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 2Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 3Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 4Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 5Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 6Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 7Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 8Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 9Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting 10
Disposable 1 1/4" Tungsten Micro Needle, Ins., Straight...
7 1/2" Bayonet Monopolar Forceps, Ins., Serrated...
... the art in inverted microscopy from Zeiss. ... range of ICS objectives, with innovative condensers ... an unusual scope of sophisticated documentation and ... designed. And Axiovert 200 M, fully motorized, ...
... TS100 is an innovative and efficient ... tool complements any research facility. Improved ... Nikon offers the TS100 binocular and ... model comes with a photo port ...
Medicine Products: